HIMSS 2024: Robin Goldsmith on Bridging Health Equity Gaps Through Digital Transformation

 

The latest episode of Healthcare Rethink, a FinThrive podcast, heads into the heart of HIMSS 2024. The conversation centers around digital transformation and its pivotal role in bridging health equity gaps. Robin Goldsmith, the Global Lead for Connected Health & Innovation at Verizon Business, shares insights from this year’s event, emphasizing the transformative power of technology in healthcare.

The episode, hosted by Brian Urban, unpacks the significant strides in healthcare technology. Robin Goldsmith discusses several key initiatives that Verizon is involved in, such as improving connectivity for remote Alaskan tribes and integrating health services within community banks. These projects, with their tangible benefits, enhance access to healthcare and address critical social determinants of health. This approach underscores a larger trend at HIMSS 2024, where digital transformation serves as a bridge to reduce health disparities.

Expanding on the theme of digital transformation at HIMSS 2024, the discussion also touches upon cybersecurity’s increasing importance in the healthcare sector. The urgency for robust security measures has never been more apparent given recent significant cyber-attacks. Goldsmith highlighted how enhanced security protocols are integral to safeguarding patient data and ensuring the continuity of healthcare services, thereby supporting the broader goals of health equity and access.

The podcast episode encapsulates the spirit of HIMSS 2024, showcasing how innovative technologies and thoughtful strategies are crucial in shaping a more equitable healthcare landscape. As digital transformation continues to evolve, its role in facilitating access to healthcare for underserved populations becomes increasingly vital, pointing towards a future where technology and healthcare go hand in hand in overcoming barriers to health equity.

Recent Episodes

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…